siRNA-mediated inhibition of SOCS1 function enhances the immunostimulatory capacity of dendritic cells and may lead to more effective cancer vaccines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Bob Crimi
References
Shen, L., Evel-Kaber, K., Strube, R. & Chen, S.Y. Nat. Biotechnol. 22, 1546–1553 (2004).
Duan, L., Reddi, A.L., Ghosh, A., Dimri, M. & Band, H. Immunity 21, 7–17 (2004).
Chen, L. Nat. Rev. Immunol. 4, 336–347 (2004).
Marrack, P. & Kappler, J. Annu. Rev. Immunol. 22, 765–787 (2004).
Kubo, M., Hanada, T. & Yoshimura, A. Nat. Immunol. 4, 1169–1176 (2003).
Hanada, T. et al. Immunity 19, 437–450 (2003).
Egen, J.G., Kuhns, M.S. & Allison, J.P. Nat. Immunol. 3, 611–618 (2002).
Hou, W.S. & Van Parijs, L. Nat. Immunol. 5, 583–589 (2004).
Grohmann, U., Fallarino, F. & Puccetti, P. Trends Immunol. 24, 242–248 (2003).
Mellor, A.L. & Munn, D.H. Nat. Rev. Immunol. 4, 762–774 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilboa, E. Knocking the SOCS1 off dendritic cells. Nat Biotechnol 22, 1521–1522 (2004). https://doi.org/10.1038/nbt1204-1521
Issue date:
DOI: https://doi.org/10.1038/nbt1204-1521
This article is cited by
-
Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously
Cancer Immunology, Immunotherapy (2012)
